Company intelligence / Profile preview

Hyalein

Osaka, Osaka, Japan

Ownership: Private
Employees: ~4000
Development stage: Other

Overview

Santen Pharmaceutical is a specialized pharmaceutical company primarily focused on the ophthalmic field. Headquartered in Japan, the company holds a leading market share in the Japanese prescription ophthalmic drug market and maintains a significant global presence. Its product portfolio includes treatments for glaucoma, dry eye, and retinal diseases, with its most recognized brand being Hyalein (purified sodium hyaluronate) for corneal and conjunctival epithelial disorders. Santen is actively expanding its pipeline through internal R&D and strategic partnerships to address unmet needs in vision care worldwide.

Therapeutic areas: ImmunologyOphthalmology
Modalities: Small moleculeBiologicAntibodyGene therapy
Industry: Biotech

Partnerships

BayerRegeneron PharmaceuticalsUbe IndustriesTracon Pharmaceuticals

Beyond the preview

Go deeper on Hyalein.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hyalein.

Explore the full profile